Home Tags Silverback Therapeutics

Tag: Silverback Therapeutics

Interim Results from Phase 1/1b Study of SBT6050 Alone or In...

ADC Review | Editorial Team
Interim clinical results from a Phase 1/1b clinical study of SBT6050 as a monotherapy and in combination with pembrolizumab in patients with advanced or...
Photo: Before the pandemic - the annual meeting of the AACR/American Association for Cancer Research: Photo courtesy: 2015 AACR/Todd Buchanan.

AACR 2020: SBT6050 Demonstrates Potent Activation of Human Myeloid Cells and...

ADC Review | Editorial Team
Preclinical data for the ImmunoTAC™ candidate SBT6050, being developed by Silverback Therapeutics, presented during the American Association for Cancer Research's (AACR) Virtual Annual Meeting...

How the Next Generation Antibody Drug Conjugates Expands Beyond Cytotoxic Payloads...

Jon Gingrich
Antibody-drug Conjugates or ADCs combine the selectivity of antibodies with the efficacy of small molecule drugs, allowing for more precise, targeted, therapeutic applications. Combining the...

Silverback Raises U.S. $78.5 Million to Advance SBT6050 into the Clinic...

ADC Review | Editorial Team
Seattle-based Silverback Therapeutics™, a biopharmaceutical company pioneering a new class of immune-modulating ImmunoTAC™ drug conjugates targeting previously inaccessible disease pathways, confirmed that it has...
ADC Review, Journal of Antibody-drug Conjugates
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policymakers.

Latest

Peer Review

© 2013-2020 Sunvalley Communication, LLC. All Rights Reserved.

X